Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
British Journal of Clinical Pharmacology|March 31, 2015
Treatment of spontaneous preterm labour with retosiban: a phase 2 proof-of-concept studySteven Thornton, Hugh Miller, Guillermo Valenzuela, et al.Journal of Clinical Pharmacology|January 23, 2015
Utility of concentration-effect modeling and simulation in a thorough QT study of losmapimodApril M Barbour, Mindy Magee, Bonnie Shaddinger, et al.British Journal of Clinical Pharmacology|May 31, 2017
Treatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging studySteven Thornton, Guillermo Valenzuela, Charlotte Baidoo, et al.Journal of Clinical Pharmacology|December 7, 2016
Markov Mixed Effects Modeling Using Electronic Adherence Monitoring Records Identifies Influential Covariates to HIV Preexposure ProphylaxisKumpal Madrasi, Ayyappa Chaturvedula, Jessica E Haberer, et al.Journal of Pain Research|October 25, 2017
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplastyNeil Singla, Harold S Minkowitz, David G Soergel, et al.Heart Rhythm|September 5, 2021
Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic riskAlexander Burashnikov, Hector Barajas-Martinez, Robert Cox, et al.Journal of Clinical Pharmacology|July 3, 2002
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteersHenry J Pieniaszek, Sherwin K B Sy, William Ebling, et al.British Journal of Clinical Pharmacology|December 11, 2012
Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteersApril M Barbour, Lea Sarov-Blat, Gengqian Cai, et al.Journal of Clinical Pharmacology|July 15, 2003
Medication errors: an analysis comparing PHICO's closed claims data and PHICO's Event Reporting Trending System (PERTS)David M Benjamin, Robert F PendrakJournal of Clinical Pharmacology|December 5, 2002
Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteersMichael J Fossler, William F Ebling, Su Ma, et al.Pageof 5